Stock research log
$MRK Insider Trading
Merck & Co., Inc.
17
Alerts Listed
0
Insider Buys 30d
0
Insider Sells 30d
This page is InsiderWatch’s research log for MRK: the alerts we sent on this stock, timestamped, plus recent insider buying and selling reported to the SEC on Form 4.
Price and Our Alerts
$MRK price
Daily closing prices
3M change
+14.5%
1Y high
$156.45
1Y low
$85.78
Our alerts
17
in this window
Prices from public market data and may be delayed. Markers show the days our alerts on this stock fired. Not investment advice.
Our Alerts on $MRK
| Sent (ET) | Call | Alert |
|---|---|---|
| Oct 31, 5:47 AM | NEUTRAL | Moderna-Merck melanoma vaccine wins Phase 3 trial |
| Oct 26, 11:47 AM | NEUTRAL | Merck's sac-TMT extends survival in endometrial cancer trial |
| Oct 2, 2:25 AM | NEUTRAL | Medicare finalizes global-benchmark rebates for Part B drugs |
| Sep 30, 8:45 AM | NEUTRAL | Merck's tulisokibart hits Phase 2b eczema goals |
| Sep 28, 9:09 AM | NEUTRAL | FDA rebuffs fast-track for Merck-Daiichi lung cancer drug |
| Sep 24, 7:03 AM | BULLISH | Merck eye drug hits goal in pivotal DME trial |
| Sep 22, 7:07 AM | NEUTRAL | Merck wins label expansion for WINREVAIR |
| Sep 21, 6:55 AM | NEUTRAL | Japan approves subcutaneous Keytruda for Merck |
| Sep 18, 7:11 AM | NEUTRAL | Merck's Keytruda-Padcev wins positive EU opinion in bladder cancer |
| Sep 14, 6:24 AM | NEUTRAL | Perspective Therapeutics partners with Merck on Keytruda combo trial |
| Sep 13, 7:55 AM | BEARISH | Gilead's Trodelvy misses endpoints in Phase 3 lung cancer trial |
| Sep 3, 5:14 PM | NEUTRAL | Generic sugammadex launch pressures Merck's Bridion |
| Aug 28, 12:37 PM | NEUTRAL | Moderna, Merck melanoma vaccine wins late-stage trial |
| Aug 24, 10:22 AM | NEUTRAL | Merck-Moderna cancer vaccine clears major hurdle |
| Aug 21, 3:32 PM | NEUTRAL | Merck mRNA cancer vaccine hits Phase 3 melanoma goal |
| Aug 20, 9:35 AM | NEUTRAL | Moderna, Merck report cancer-vaccine trial win |
| Aug 19, 6:48 AM | NEUTRAL | Moderna, Merck cancer vaccine wins first Phase 3 trial |
Every alert we sent on MRK is listed after a short delay, in the order it went out. The call shown is the one in the alert as sent.
Recent Insider Activity
Open-market buys and sells in MRK by the company’s own officers, directors, and large holders, as reported to the SEC on Form 4 in roughly the last 30 days. New to the filing? Read what a Form 4 is and what the transaction codes mean.
| Filed (ET) | Insider | Action | Value |
|---|---|---|---|
| Aug 13 | Guindo ChirfiEVP, Access, Policy & Comms | SELL | $1.4M |
| Aug 13 | Zachary JenniferEVP, General Counsel | SELL | $10.7M |
| Aug 12 | DeLuca Richard R.EVP&Pres, Merck Animal Heallth | SELL | $5.9M |
| Aug 7 | Maraldo David R.EVP & Pres. MMD | SELL | $2.4M |
| Aug 7 | Williams David MichaelEVP,Chief Info&Digital Officer | SELL | $6.8M |
| Aug 7 | Guindo ChirfiEVP, Access, Policy & Comms | SELL | $2.0M |
Sourced from public SEC Form 4 filings. Buys shown are open-market purchases; routine grants and plan sales are filtered out before a trade reaches this log.
Congress Trading in $MRK
Members of Congress who disclosed trades in MRK under the STOCK Act since we began tracking. Each name links to that member’s full page. Amounts are the disclosed ranges (see how the ranges work) and filings can arrive up to 45 days after the trade.
| Member | Action | Amount |
|---|---|---|
| Maria Elvira SalazarHouse | SELL | $1,001 - $15,000 |
| Maria Elvira SalazarHouse | BUY | $15,001 - $50,000 |
| Maria Elvira SalazarHouse | BUY | $15,001 - $50,000 |
| Josh GottheimerHouse | BUY | $1,001 - $15,000 |
| Julie JohnsonHouse | SELL | $1,001 - $15,000 |
| Gilbert CisnerosHouse | BUY | $1,001 - $15,000 |
Disclosed amounts are ranges. Filing and trade dates, who in the household traded, and full histories are part of the subscriber dashboard.
See the research log across all stocks, this week’s insider buying, or the congress trading tracker.
Get the Next MRK Alert When It Fires.
Everything here is already public. Subscribers usually got it within minutes. Pro members get every alert. Free for 7 days, cancel any time.
Try Free for 7 DaysInsiderWatch is an informational research service based on publicly available information only and is not financial, investment, legal, or tax advice. The call shown is a reading of the event, not a recommendation to trade.